Summit Therapeutics Inc Financials

SMMT

Export CSV

Key Financial Metrics

Revenue

Summit Therapeutics Inc generated $0 in revenue in fiscal year 2024.

EBITDA

-$225.9M

YoY+62.9%

Summit Therapeutics Inc's EBITDA was -$225.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 62.9% from the prior year.

Free Cash Flow

-$142.2M

YoY-85.0%

Summit Therapeutics Inc generated -$142.2M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents a decrease of 85.0% from the prior year.

Net Income

-$221.3M

YoY+64.0%

Summit Therapeutics Inc reported -$221.3M in net income in fiscal year 2024. This represents an increase of 64.0% from the prior year.

EPS (Diluted)

$-0.31

YoY+68.7%

Summit Therapeutics Inc earned $-0.31 per diluted share in fiscal year 2024. This represents an increase of 68.7% from the prior year.

Cash & Debt

$104.9M

YoY+46.8%

5Y CAGR+10.4%

Summit Therapeutics Inc held $104.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

738M

YoY+5.1%

5Y CAGR+61.5%

Summit Therapeutics Inc had 738M shares outstanding in fiscal year 2024. This represents an increase of 5.1% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$150.8M

YoY+153.5%

5Y CAGR+30.5%

Summit Therapeutics Inc invested $150.8M in research and development in fiscal year 2024. This represents an increase of 153.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$139K

YoY+8.6%

5Y CAGR-7.5%

Summit Therapeutics Inc invested $139K in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 8.6% from the prior year.

SMMT Income Statement

Metric	FY24	FY24	FY24	FY22	FY21	FY20
Revenue	$0	$0-100.0%	$705K-61.0%	$1.8M+110.3%	$860K+15.7%	$743K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$150.8M+153.5%	$59.5M+14.4%	$52.0M-39.1%	$85.4M+60.2%	$53.3M+33.8%	$39.8M
SG&A Expenses	$60.5M+100.0%	$30.3M+13.2%	$26.7M+13.3%	$23.6M+22.8%	$19.2M+70.5%	$11.3M
Operating Income	-$226.0M+62.9%	-$609.6M-745.7%	-$72.1M+16.4%	-$86.2M-62.0%	-$53.2M-93.6%	-$27.5M
Interest Expense	$8.7M-47.2%	$16.5M+274.0%	$4.4M+1718.6%	$242K-5.1%	$255K-12.4%	$291K
Income Tax	N/A	N/A	N/A	$0+100.0%	-$213K-691.7%	$36K
Net Income	-$221.3M+64.0%	-$614.9M-680.5%	-$78.8M+11.1%	-$88.6M-68.1%	-$52.7M-80.9%	-$29.1M
EPS (Diluted)	$-0.31+68.7%	$-0.99-141.5%	$-0.41+38.8%	$-0.67+11.8%	$-0.76+14.6%	$-0.89

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'24	Q3'25	Q3'25	Q4'24
Revenue	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$131.1M-37.0%	$208.0M+305.8%	$51.3M	N/A	$37.7M+22.5%	$30.8M-0.2%	$30.9M	N/A
SG&A Expenses	$103.1M-71.4%	$360.4M+2212.4%	$15.6M	N/A	$20.7M+49.5%	$13.8M+19.9%	$11.5M	N/A
Operating Income	N/A	N/A	N/A	N/A	-$58.4M+2.1%	-$59.6M-40.6%	-$42.4M	N/A
Interest Expense	$0	$0	$0	N/A	$2.5M-20.9%	$3.1M-0.6%	$3.1M	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$231.8M+59.0%	-$565.7M-799.2%	-$62.9M	N/A	-$56.3M+6.8%	-$60.4M-38.9%	-$43.5M	N/A
EPS (Diluted)	$-0.31+59.2%	$-0.76-744.4%	$-0.09	N/A	$-0.08+11.1%	$-0.09-50.0%	$-0.06	N/A

SMMT Balance Sheet

Metric	FY24	FY24	FY24	FY22	FY21	FY20
Total Assets	$435.6M+114.6%	$202.9M-69.4%	$664.2M+485.8%	$113.4M+10.6%	$102.5M+6.5%	$96.2M
Current Assets	$423.8M+123.4%	$189.7M-71.1%	$656.7M+574.9%	$97.3M+11.0%	$87.7M+10.1%	$79.6M
Cash & Equivalents	$104.9M+46.8%	$71.4M-79.5%	$348.6M+385.6%	$71.8M+8.1%	$66.4M+4.0%	$63.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$0-100.0%	$349K-76.2%	$1.5M+342.3%	$331K-38.8%	$541K
Goodwill	$1.9M-1.5%	$1.9M+5.3%	$1.8M-10.5%	$2.0M-1.0%	$2.0M+3.5%	$2.0M
Total Liabilities	$46.8M-62.6%	$125.3M-76.7%	$537.5M+1686.4%	$30.1M+30.6%	$23.0M+32.6%	$17.4M
Current Liabilities	$41.7M+104.5%	$20.4M-47.4%	$38.8M+51.4%	$25.6M+28.8%	$19.9M+44.5%	$13.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$388.7M+400.4%	$77.7M-38.7%	$126.7M+52.1%	$83.3M+4.8%	$79.5M+0.7%	$78.9M
Retained Earnings	-$1.2B-22.3%	-$993.3M-162.5%	-$378.3M-26.3%	-$299.5M-42.0%	-$210.9M-33.3%	-$158.2M

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'24	Q3'25	Q3'25	Q4'24
Total Assets	$261.7M-19.2%	$324.0M-15.6%	$383.8M-11.9%	$435.6M-13.4%	$502.9M+47.1%	$341.9M+93.4%	$176.8M-12.9%	$202.9M
Current Assets	$246.5M-20.3%	$309.2M-16.6%	$370.8M-12.5%	$423.8M-13.6%	$490.3M+49.1%	$328.8M+101.4%	$163.3M-13.9%	$189.7M
Cash & Equivalents	$238.6M-19.9%	$297.9M+40.8%	$211.5M+101.7%	$104.9M+11.8%	$93.8M+229.8%	$28.4M-53.6%	$61.3M-14.2%	$71.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Goodwill	$2.0M-2.0%	$2.0M+6.0%	$1.9M+3.2%	$1.9M-6.4%	$2.0M+5.9%	$1.9M+0.3%	$1.9M-1.0%	$1.9M
Total Liabilities	$69.5M+7.5%	$64.6M+63.6%	$39.5M-15.6%	$46.8M-27.9%	$64.9M-55.8%	$146.8M+10.7%	$132.6M+5.8%	$125.3M
Current Liabilities	$64.9M+7.6%	$60.3M+73.0%	$34.9M-16.4%	$41.7M-29.3%	$59.0M-57.9%	$140.2M+498.0%	$23.4M+14.9%	$20.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$192.3M-25.9%	$259.4M-24.7%	$344.3M-11.4%	$388.7M-11.2%	$437.9M+124.5%	$195.1M+341.2%	$44.2M-43.1%	$77.7M
Retained Earnings	-$2.1B-12.6%	-$1.8B-44.3%	-$1.3B-5.2%	-$1.2B-5.3%	-$1.2B-5.1%	-$1.1B-5.8%	-$1.0B-4.4%	-$993.3M

SMMT Cash Flow Statement

Metric	FY24	FY24	FY24	FY22	FY21	FY20
Operating Cash Flow	-$142.1M-85.1%	-$76.8M-84.6%	-$41.6M+42.7%	-$72.6M-50.9%	-$48.1M-131.8%	-$20.8M
Capital Expenditures	$139K+8.6%	$128K-79.5%	$624K+103.9%	$306K-27.3%	$421K+105.4%	$205K
Free Cash Flow	-$142.2M-85.0%	-$76.9M-82.2%	-$42.2M+42.1%	-$72.9M-50.2%	-$48.5M-131.5%	-$21.0M
Investing Cash Flow	-$205.3M+65.1%	-$587.8M-94094.6%	-$624K-103.9%	-$306K+27.3%	-$421K-23.5%	-$341K
Financing Cash Flow	$381.2M+340.7%	$86.5M-86.1%	$620.2M+696.0%	$77.9M+54.1%	$50.6M+2.1%	$49.5M
Dividends Paid	N/A	N/A	N/A	N/A	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'24	Q3'25	Q3'25	Q4'24
Operating Cash Flow	N/A	N/A	-$61.2M	N/A	N/A	N/A	-$30.1M	N/A
Capital Expenditures	N/A	N/A	$422K	N/A	N/A	N/A	$4K	N/A
Free Cash Flow	N/A	N/A	-$61.6M	N/A	N/A	N/A	-$30.1M	N/A
Investing Cash Flow	N/A	N/A	$160.1M	N/A	N/A	N/A	$19.9M	N/A
Financing Cash Flow	N/A	N/A	$7.7M	N/A	N/A	N/A	$485K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SMMT Financial Ratios

Metric	FY24	FY24	FY24	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-10225.4%-5461.1pp	-4764.3%+1420.9pp	-6185.2%-2487.7pp	-3697.6%
Net Margin	N/A	N/A	-11174.8%-6276.9pp	-4897.8%+1229.7pp	-6127.6%-2207.4pp	-3920.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-50.8%+252.2pp	-303.0%-291.1pp	-11.9%+66.3pp	-78.1%-26.7pp	-51.4%-21.2pp	-30.3%
Current Ratio	10.15+0.9	9.30-7.6	16.93+13.1	3.80-0.6	4.41-1.4	5.78
Debt-to-Equity	0.12-1.5	1.61-2.6	4.24+3.9	0.36+0.1	0.29+0.1	0.22
FCF Margin	N/A	N/A	-5986.7%-1957.2pp	-4029.5%+1613.8pp	-5643.3%-2822.0pp	-2821.3%

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'24	Q3'25	Q3'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-88.6%+86.0pp	-174.6%-158.2pp	-16.4%	N/A	-11.2%+6.5pp	-17.7%+6.9pp	-24.6%	N/A
Current Ratio	3.80-1.3	5.13-5.5	10.63+0.5	10.15+1.8	8.31+6.0	2.35-4.6	6.97-2.3	9.30
Debt-to-Equity	0.36+0.1	0.25+0.1	0.110.0	0.12-0.0	0.15-0.6	0.75-2.2	3.00+1.4	1.61
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is Summit Therapeutics Inc's annual revenue?

Summit Therapeutics Inc (SMMT) reported $0 in revenue for fiscal year 2024.

Is Summit Therapeutics Inc profitable?

No, Summit Therapeutics Inc (SMMT) reported a net income of -$221.3M in fiscal year 2024.

What is Summit Therapeutics Inc's earnings per share (EPS)?

Summit Therapeutics Inc (SMMT) reported diluted earnings per share of $-0.31 for fiscal year 2024.

What is Summit Therapeutics Inc's EBITDA?

Summit Therapeutics Inc (SMMT) had EBITDA of -$225.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Summit Therapeutics Inc's free cash flow?

Summit Therapeutics Inc (SMMT) generated -$142.2M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Summit Therapeutics Inc's operating cash flow?

Summit Therapeutics Inc (SMMT) generated -$142.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Summit Therapeutics Inc's total assets?

Summit Therapeutics Inc (SMMT) had $435.6M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Summit Therapeutics Inc's capital expenditures?

Summit Therapeutics Inc (SMMT) invested $139K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Summit Therapeutics Inc spend on research and development?

Summit Therapeutics Inc (SMMT) invested $150.8M in research and development during fiscal year 2024.

How many shares does Summit Therapeutics Inc have outstanding?

Summit Therapeutics Inc (SMMT) had 738M shares outstanding as of fiscal year 2024.

What is Summit Therapeutics Inc's current ratio?

Summit Therapeutics Inc (SMMT) had a current ratio of 10.15 as of fiscal year 2024, which is generally considered healthy.

What is Summit Therapeutics Inc's debt-to-equity ratio?

Summit Therapeutics Inc (SMMT) had a debt-to-equity ratio of 0.12 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Summit Therapeutics Inc's return on assets (ROA)?

Summit Therapeutics Inc (SMMT) had a return on assets of -50.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.